Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vitamin d levels after heart attack: a simple fix for major risks?

NCT ID NCT02996721

Disease control Sponsor: Intermountain Health Care, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether getting vitamin D levels above 40 ng/mL after a heart attack could reduce the chance of death, another heart attack, stroke, or heart failure hospitalization. About 634 heart attack patients were split into two groups: one got standard care, and the other got extra vitamin D3 to raise their levels. The goal was to see if normalizing vitamin D makes a real difference in preventing major heart-related events.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vitamin D3 (cholecalciferol)
What this could lead to
If it works, this could point toward a simple, low-cost way to lower the risk of serious heart problems after a heart attack.
What could go wrong
This is a completed Phase 4 trial with 634 participants, but the results may not apply to everyone. Vitamin D is generally safe, but high doses can cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

634 people

The number who actually took part.

Started

Apr 2017

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients, both male and female, \>18 years old 2. Undergone angiography for a MI (troponin positive \[\>0.04 ng/mL\] and ACS diagnosis) within the past month 3. Receive follow-up care at an Intermountain Healthcare facility 4. Not taking or taking \<1000 IU of vitamin D daily within the last 3 months 5. Willing to provide informed consent and participate in follow-up visits Exclusion Criteria: 1. Hypersensitivity to vitamin D products 2. History of previous vitamin D supplementation of \>1000 IU daily within the past 3 months (i.e., \>40% of the days during the past 3 months). 3. Systemic disease (including terminal cancer, cirrhosis, end stage COPD, etc) with a reduced (\<12 months) life expectancy 4. Hypercalcemia (calcium levels \>10.6 mg/dL) 5. Subject participation in previous investigational interventional studies within 30 days of the current study. 6. History of psychiatric illness/condition that would interfere with their ability to understand or complete the requirements of the study, a condition that in the opinion of the investigator or their designee places the subject at an unacceptable risk as a participant. 7. Pregnant and/or lactating women and women of child bearing potential who are not using acceptable means of contraception as determined by the clinical investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebral vascular accident are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Death heart failure myocardial infarction stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cerebral vascular accident Death Heart failure hospitalization Myocardial infarction

Contacts and locations

Locations

  • Intermountain Medical Center

    Murray, Utah, 84157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.